7 recruiting, 4 completed, 3 active not recruiting, 3 terminated. 10 Phase 2, 4 Phase 1, 4 Phase 3, 1 Not applicable.
Follow Erwinase: new trials by email Literature Review of Erwinase trials Research Report on Erwinase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 26 | 2026-05-13 | 2026-10-16 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 461 | 2020-12-17 | 2026-11-12 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Ma-Spore ALL 2020 Study Prednisolone, Dexamethasone, Vincristine - B Lymphoblastic Leukemia | Phase 2 | Recruiting | National University Hospital, Singapore | 500 | 2020-03-04 | 2024-03-28 |
| AflacLL1901 (CHOA-AML) Cytarabine, Daunorubicin, Erwinase - Acute Myeloid Leukemia, AML, Childhood | Phase 2 | Terminated | Emory University | 8 | 2020-01-24 | 2022-06-15 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-11-12 |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Blinatumomab, Bortezomib, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric | Phase 3 | Recruiting | Martin Schrappe | 5000 | 2018-07-15 | 2025-04-06 |
| Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Fludarabine, Cytarabine, Erwinase - Hematologic Malignancy | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2018-05-01 | 2018-06-26 | |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Children's Oncology Group | 80 | 2017-06-19 | 2026-10-01 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome | Phase 3 | Active not recruiting | Children's Oncology Group | 280 | 2015-12-23 | 2026-08-19 |
| Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Bortezomib, Vorinostat, Mitoxantrone - Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | St. Jude Children's Research Hospital | 12 | 2015-04-14 | 2018-03-07 |
| 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) Erwinase - Acute Myeloid Leukemia | Phase 1 | Completed | Ashkan Emadi | 5 | 2014-04-01 | 2018-03-12 |
| Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) Erwinase, Vincristine, Dexamethasone - Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase | Phase 1 | Terminated | Therapeutic Advances in Childhood Leukemia Consortium | 1 | 2009-04-13 | 2019-02-19 |
| Erwinase Study in Patients With Acute Lymphoblastic Leukemia Erwinase - Leukemia | Not applicable | Completed | M.D. Anderson Cancer Center | 33 | 2007-05-01 | 2014-09-11 |
| Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma Erwinase - Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 87 | 2006-06-01 | 2017-04-26 |
| Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma Kidrolase, Methotrexate, Dexamethasone - Lymphoma, Non-Hodgkin | Phase 2 | Completed | University Hospital, Limoges | 40 | 2006-02-01 | 2013-02-28 |
| Erwinase Master Treatment Protocol Erwinia L-asparaginase - Leukemia, Acute Lymphoblastic, Acute Lymphoid Leukemia | No longer available | Phoenix Children's Hospital | 2026-01-23 |
Burkitt Lymphoma (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia, Myeloid, Acute (6) · Down Syndrome (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Hematologic Neoplasms (1) · Hypersensitivity (1) · Leukemia, Prolymphocytic (1) · Lymphoma, B-Cell (1) · Lymphoma, Extranodal NK-T-Cell (1)
Children's Oncology Group (3) · National Cancer Institute (NCI) (3) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · St. Jude Children's Research Hospital (2) · Ashkan Emadi (1) · Emory University (1) · Martin Schrappe (1) · National University Hospital, Singapore (1) · Phoenix Children's Hospital (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · University Hospital, Limoges (1) · University of Washington (1)
United States (15) · Puerto Rico (6) · Australia (5) · Canada (4) · New Zealand (2) · Austria (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Malaysia (1) · Saudi Arabia (1) · Singapore (1) · Slovakia (1)
Allen Eng Juh Yeoh, MBBS (1) · Amandeep Salhotra (1) · Ashkan Emadi, MD, PhD (1) · Erin H Breese (1) · Heather Grossman, MD (1) · Himalee Sabnis, MD (1) · Ibrahim Aldoss (1) · Jason N Berman (1) · Martin Schrappe, MD (1) · Maureen M O'Brien (1) · Paul Gaynon, MD (1) · Robert J. Wells, MD (1) · Ryan D. Cassaday, MD (1) · Sima Jeha, MD (1)
PMID 41671463, PMID 35622074, PMID 21123825, PMID 32683126, PMID 33843815, PMID 33844429, PMID 35007127, PMID 35129146, PMID 38107263, PMID 38841802, PMID 38947228, PMID 39651791, PMID 41124669, PMID 42497367, PMID 42748428
U10CA180886 (6), P30CA033572 (2), 2019 (1)